CA3033964A1 - Gaba(a) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma - Google Patents

Info

Publication number

CA3033964A1

CA3033964A1 CA3033964A CA3033964A CA3033964A1 CA 3033964 A1 CA3033964 A1 CA 3033964A1 CA 3033964 A CA3033964 A CA 3033964A CA 3033964 A CA3033964 A CA 3033964A CA 3033964 A1 CA3033964 A1 CA 3033964A1

Authority

CA

Canada

Prior art keywords

compound

pharmaceutically acceptable

acceptable salt

cyclopropyl

compounds

Prior art date

2016-08-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 238000000034 method Methods 0.000 title claims description 30
• 208000006673 asthma Diseases 0.000 title abstract description 22
• 230000004054 inflammatory process Effects 0.000 title abstract description 12
• 208000002200 Respiratory Hypersensitivity Diseases 0.000 title abstract description 10
• 230000010085 airway hyperresponsiveness Effects 0.000 title abstract description 10
• 208000037883 airway inflammation Diseases 0.000 title abstract description 3
• 102000004300 GABA-A Receptors Human genes 0.000 title description 2
• 108090000839 GABA-A Receptors Proteins 0.000 title description 2
• 150000001875 compounds Chemical class 0.000 claims abstract description 274
• 150000003839 salts Chemical class 0.000 claims description 68
• 229910052731 fluorine Inorganic materials 0.000 claims description 48
• 229910052801 chlorine Inorganic materials 0.000 claims description 46
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 44
• 229910052739 hydrogen Inorganic materials 0.000 claims description 37
• 150000001733 carboxylic acid esters Chemical class 0.000 claims description 30
• 229910052794 bromium Inorganic materials 0.000 claims description 24
• -1 -C.ident.CH Chemical group 0.000 claims description 19
• 206010035664 Pneumonia Diseases 0.000 claims description 15
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 15
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 15
• 239000003814 drug Substances 0.000 claims description 14
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 13
• 239000008194 pharmaceutical composition Substances 0.000 claims description 13
• 229910052805 deuterium Inorganic materials 0.000 claims description 11
• 201000010099 disease Diseases 0.000 claims description 11
• JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 9
• 108010081348 HRT1 protein Hairy Proteins 0.000 claims description 9
• 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims description 9
• 150000001408 amides Chemical class 0.000 claims description 9
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
• 208000019693 Lung disease Diseases 0.000 claims description 8
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
• 150000007970 thio esters Chemical class 0.000 claims description 8
• 238000011161 development Methods 0.000 claims description 7
• 125000004122 cyclic group Chemical group 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• AUHBCNJHXCDLMK-UHFFFAOYSA-N diazepine-1-carboxamide Chemical compound NC(=O)N1C=CC=CC=N1 AUHBCNJHXCDLMK-UHFFFAOYSA-N 0.000 claims description 4
• 229910052740 iodine Inorganic materials 0.000 claims description 4
• 238000004519 manufacturing process Methods 0.000 claims description 4
• UXZDPIMYMVDVAS-UHFFFAOYSA-N pyrrolo[1,2-a][1,4]diazepin-9-one Chemical compound C1=C2N(C=CC=N1)C=CC2=O UXZDPIMYMVDVAS-UHFFFAOYSA-N 0.000 claims description 4
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
• 229920006395 saturated elastomer Polymers 0.000 claims description 3
• QRKPPWPLSQRGSU-UHFFFAOYSA-N diazepine-1-carboxylic acid Chemical compound OC(=O)N1C=CC=CC=N1 QRKPPWPLSQRGSU-UHFFFAOYSA-N 0.000 claims description 2
• 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
• 125000006416 CBr Chemical group BrC* 0.000 claims 5
• 125000000896 monocarboxylic acid group Chemical group 0.000 claims 5
• ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 claims 5
• 125000006414 CCl Chemical group ClC* 0.000 claims 3
• 125000006415 CF Chemical group FC* 0.000 claims 3
• 125000006417 CH Chemical group [H]C* 0.000 claims 3
• 150000001735 carboxylic acids Chemical class 0.000 claims 3
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
• ZGUBPQDGZULKIU-SNVBAGLBSA-N (4R)-8-bromo-4-methyl-6-pyridin-2-yl-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid Chemical compound BrC=1C=CC2=C(C(=N[C@@H](C=3N2C=NC=3C(=O)O)C)C2=NC=CC=C2)C=1 ZGUBPQDGZULKIU-SNVBAGLBSA-N 0.000 claims 1
• OSBXEAZWQGBYFU-SNVBAGLBSA-N (4R)-8-bromo-6-(2-fluorophenyl)-4-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid Chemical compound BrC=1C=CC2=C(C(=N[C@@H](C=3N2C=NC=3C(=O)O)C)C2=C(C=CC=C2)F)C=1 OSBXEAZWQGBYFU-SNVBAGLBSA-N 0.000 claims 1
• PFFFIBRKJLUIAF-SNVBAGLBSA-N (4R)-8-chloro-6-(2-fluorophenyl)-4-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid Chemical compound ClC=1C=CC2=C(C(=N[C@@H](C=3N2C=NC=3C(=O)O)C)C2=C(C=CC=C2)F)C=1 PFFFIBRKJLUIAF-SNVBAGLBSA-N 0.000 claims 1
• MMEBANRNRMFELC-GFCCVEGCSA-N (4R)-8-cyclopropyl-6-(2-fluorophenyl)-4-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid Chemical compound C1(CC1)C=1C=CC2=C(C(=N[C@@H](C=3N2C=NC=3C(=O)O)C)C2=C(C=CC=C2)F)C=1 MMEBANRNRMFELC-GFCCVEGCSA-N 0.000 claims 1
• NREDTYQJFPCUFV-GFCCVEGCSA-N (4R)-8-ethynyl-4-methyl-6-pyridin-2-yl-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid Chemical compound C(#C)C=1C=CC2=C(C(=N[C@@H](C=3N2C=NC=3C(=O)O)C)C2=NC=CC=C2)C=1 NREDTYQJFPCUFV-GFCCVEGCSA-N 0.000 claims 1
• KVWUUAODCGQTCB-GFCCVEGCSA-N (4r)-8-ethynyl-6-(2-fluorophenyl)-4-methyl-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid Chemical compound N([C@@H](C1=C(C(O)=O)N=CN1C1=CC=C(C=C11)C#C)C)=C1C1=CC=CC=C1F KVWUUAODCGQTCB-GFCCVEGCSA-N 0.000 claims 1
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
• 230000002829 reductive effect Effects 0.000 abstract description 39
• 230000000694 effects Effects 0.000 abstract description 35
• 102000027484 GABAA receptors Human genes 0.000 abstract description 23
• 108091008681 GABAA receptors Proteins 0.000 abstract description 23
• 238000011282 treatment Methods 0.000 abstract description 11
• 230000002093 peripheral effect Effects 0.000 abstract description 2
• 101001002508 Homo sapiens Immunoglobulin-binding protein 1 Proteins 0.000 abstract 1
• 102100021042 Immunoglobulin-binding protein 1 Human genes 0.000 abstract 1
• 238000005192 partition Methods 0.000 abstract 1
• YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 abstract 1
• 241000699670 Mus sp. Species 0.000 description 62
• 210000004027 cell Anatomy 0.000 description 52
• 239000000243 solution Substances 0.000 description 46
• 239000000203 mixture Substances 0.000 description 43
• 210000004072 lung Anatomy 0.000 description 37
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 34
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 32
• 239000000460 chlorine Substances 0.000 description 31
• 239000002253 acid Substances 0.000 description 30
• 229910052799 carbon Inorganic materials 0.000 description 30
• 210000005091 airway smooth muscle Anatomy 0.000 description 27
• 125000001424 substituent group Chemical group 0.000 description 27
• 238000003786 synthesis reaction Methods 0.000 description 26
• 210000003169 central nervous system Anatomy 0.000 description 25
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 23
• 230000015572 biosynthetic process Effects 0.000 description 23
• 239000007787 solid Substances 0.000 description 21
• 210000004681 ovum Anatomy 0.000 description 20
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 19
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 18
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 18
• 210000000287 oocyte Anatomy 0.000 description 17
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
• 125000000217 alkyl group Chemical group 0.000 description 16
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 16
• 239000002904 solvent Substances 0.000 description 16
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 16
• 241000699666 Mus <mouse, genus> Species 0.000 description 15
• 238000005481 NMR spectroscopy Methods 0.000 description 15
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
• 239000003981 vehicle Substances 0.000 description 15
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
• 239000002953 phosphate buffered saline Substances 0.000 description 14
• 238000010992 reflux Methods 0.000 description 14
• 239000000741 silica gel Substances 0.000 description 14
• 229910002027 silica gel Inorganic materials 0.000 description 14
• 210000001519 tissue Anatomy 0.000 description 14
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 13
• 238000006243 chemical reaction Methods 0.000 description 13
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 13
• 229960003529 diazepam Drugs 0.000 description 13
• 210000004969 inflammatory cell Anatomy 0.000 description 13
• 238000002347 injection Methods 0.000 description 13
• 239000007924 injection Substances 0.000 description 13
• 238000007912 intraperitoneal administration Methods 0.000 description 13
• 238000012360 testing method Methods 0.000 description 13
• 241001465754 Metazoa Species 0.000 description 12
• 230000001965 increasing effect Effects 0.000 description 12
• 238000005259 measurement Methods 0.000 description 12
• 230000004044 response Effects 0.000 description 12
• 238000011287 therapeutic dose Methods 0.000 description 12
• 101150041968 CDC13 gene Proteins 0.000 description 11
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 11
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
• 230000003281 allosteric effect Effects 0.000 description 11
• 210000004369 blood Anatomy 0.000 description 11
• 239000008280 blood Substances 0.000 description 11
• 239000000872 buffer Substances 0.000 description 11
• 229940079593 drug Drugs 0.000 description 11
• 125000005842 heteroatom Chemical group 0.000 description 11
• 239000011541 reaction mixture Substances 0.000 description 11
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
• 210000001744 T-lymphocyte Anatomy 0.000 description 10
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
• SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 9
• 238000011725 BALB/c mouse Methods 0.000 description 9
• 102000004127 Cytokines Human genes 0.000 description 9
• 108090000695 Cytokines Proteins 0.000 description 9
• 229910052786 argon Inorganic materials 0.000 description 9
• 125000003118 aryl group Chemical group 0.000 description 9
• 238000003556 assay Methods 0.000 description 9
• 229940049706 benzodiazepine Drugs 0.000 description 9
• 229910052757 nitrogen Inorganic materials 0.000 description 9
• 238000011002 quantification Methods 0.000 description 9
• 239000000725 suspension Substances 0.000 description 9
• 238000004809 thin layer chromatography Methods 0.000 description 9
• WCYWZMWISLQXQU-FIBGUPNXSA-N trideuteriomethane Chemical compound [2H][C]([2H])[2H] WCYWZMWISLQXQU-FIBGUPNXSA-N 0.000 description 9
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
• 206010061218 Inflammation Diseases 0.000 description 8
• 239000004480 active ingredient Substances 0.000 description 8
• 125000002619 bicyclic group Chemical group 0.000 description 8
• 125000004432 carbon atom Chemical group C* 0.000 description 8
• 238000002360 preparation method Methods 0.000 description 8
• 102000005962 receptors Human genes 0.000 description 8
• 108020003175 receptors Proteins 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• 230000007704 transition Effects 0.000 description 8
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
• 239000007995 HEPES buffer Substances 0.000 description 7
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 7
• 238000004458 analytical method Methods 0.000 description 7
• 239000012267 brine Substances 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• 239000002158 endotoxin Substances 0.000 description 7
• 210000002865 immune cell Anatomy 0.000 description 7
• 229920006008 lipopolysaccharide Polymers 0.000 description 7
• 229960002329 methacholine Drugs 0.000 description 7
• 125000002950 monocyclic group Chemical group 0.000 description 7
• 239000012044 organic layer Substances 0.000 description 7
• 239000011780 sodium chloride Substances 0.000 description 7
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
• 239000003826 tablet Substances 0.000 description 7
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
• 239000007832 Na2SO4 Substances 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
• 125000003342 alkenyl group Chemical group 0.000 description 6
• 125000000304 alkynyl group Chemical group 0.000 description 6
• 125000004429 atom Chemical group 0.000 description 6
• 239000001110 calcium chloride Substances 0.000 description 6
• 235000011148 calcium chloride Nutrition 0.000 description 6
• 229910001628 calcium chloride Inorganic materials 0.000 description 6
• 210000003979 eosinophil Anatomy 0.000 description 6
• DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 6
• 238000003818 flash chromatography Methods 0.000 description 6
• 238000000684 flow cytometry Methods 0.000 description 6
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
• 210000001853 liver microsome Anatomy 0.000 description 6
• NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 6
• 229910052938 sodium sulfate Inorganic materials 0.000 description 6
• 235000011152 sodium sulphate Nutrition 0.000 description 6
• MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 229910052717 sulfur Inorganic materials 0.000 description 6
• 210000005062 tracheal ring Anatomy 0.000 description 6
• VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 6
• 241000700199 Cavia porcellus Species 0.000 description 5
• 108010058846 Ovalbumin Proteins 0.000 description 5
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 5
• 229960004373 acetylcholine Drugs 0.000 description 5
• 230000001154 acute effect Effects 0.000 description 5
• 239000007864 aqueous solution Substances 0.000 description 5
• 239000012300 argon atmosphere Substances 0.000 description 5
• 230000027455 binding Effects 0.000 description 5
• 229940098773 bovine serum albumin Drugs 0.000 description 5
• 210000004556 brain Anatomy 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• 230000002508 compound effect Effects 0.000 description 5
• 125000000753 cycloalkyl group Chemical group 0.000 description 5
• 231100000135 cytotoxicity Toxicity 0.000 description 5
• 230000003013 cytotoxicity Effects 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• 210000003743 erythrocyte Anatomy 0.000 description 5
• 150000002148 esters Chemical class 0.000 description 5
• 125000001183 hydrocarbyl group Chemical group 0.000 description 5
• 208000015181 infectious disease Diseases 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 229910001629 magnesium chloride Inorganic materials 0.000 description 5
• 229940092253 ovalbumin Drugs 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 239000006228 supernatant Substances 0.000 description 5
• 230000009466 transformation Effects 0.000 description 5
• IECJCROEVIVLJK-UHFFFAOYSA-N 1,4-diazepine-1-carboxylic acid Chemical compound OC(=O)N1C=CC=NC=C1 IECJCROEVIVLJK-UHFFFAOYSA-N 0.000 description 4
• 238000005160 1H NMR spectroscopy Methods 0.000 description 4
• 208000023275 Autoimmune disease Diseases 0.000 description 4
• 108091006146 Channels Proteins 0.000 description 4
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
• 229930182555 Penicillin Natural products 0.000 description 4
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
• 239000002202 Polyethylene glycol Substances 0.000 description 4
• 241000700159 Rattus Species 0.000 description 4
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
• 241000269370 Xenopus <genus> Species 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
• 125000002252 acyl group Chemical group 0.000 description 4
• 238000000540 analysis of variance Methods 0.000 description 4
• 238000003491 array Methods 0.000 description 4
• 206010003246 arthritis Diseases 0.000 description 4
• 125000003710 aryl alkyl group Chemical group 0.000 description 4
• 239000002585 base Substances 0.000 description 4
• 230000003435 bronchoconstrictive effect Effects 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 230000008602 contraction Effects 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 206010012601 diabetes mellitus Diseases 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 239000012530 fluid Substances 0.000 description 4
• 229960001031 glucose Drugs 0.000 description 4
• 125000001072 heteroaryl group Chemical group 0.000 description 4
• 125000000623 heterocyclic group Chemical group 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 230000002757 inflammatory effect Effects 0.000 description 4
• 239000010410 layer Substances 0.000 description 4
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
• 210000005265 lung cell Anatomy 0.000 description 4
• 230000004060 metabolic process Effects 0.000 description 4
• 238000003305 oral gavage Methods 0.000 description 4
• 229940049954 penicillin Drugs 0.000 description 4
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
• 229910052698 phosphorus Inorganic materials 0.000 description 4
• 239000006187 pill Substances 0.000 description 4
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
• 239000000651 prodrug Substances 0.000 description 4
• 229940002612 prodrug Drugs 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• 208000005069 pulmonary fibrosis Diseases 0.000 description 4
• 150000003254 radicals Chemical class 0.000 description 4
• 125000006413 ring segment Chemical group 0.000 description 4
• 229910052710 silicon Inorganic materials 0.000 description 4
• 239000007858 starting material Substances 0.000 description 4
• 229960005322 streptomycin Drugs 0.000 description 4
• 238000006467 substitution reaction Methods 0.000 description 4
• QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 3
• SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 3
• CPHGOBGXZQKCKI-UHFFFAOYSA-N 4,5-diphenyl-1h-imidazole Chemical compound N1C=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 CPHGOBGXZQKCKI-UHFFFAOYSA-N 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 3
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
• 201000003883 Cystic fibrosis Diseases 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 102100024304 Protachykinin-1 Human genes 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
• 101800003906 Substance P Proteins 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 239000000443 aerosol Substances 0.000 description 3
• 210000001552 airway epithelial cell Anatomy 0.000 description 3
• 150000001299 aldehydes Chemical class 0.000 description 3
• 230000003110 anti-inflammatory effect Effects 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• 210000000981 epithelium Anatomy 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 229910052736 halogen Inorganic materials 0.000 description 3
• 150000002367 halogens Chemical class 0.000 description 3
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 238000002649 immunization Methods 0.000 description 3
• 230000003053 immunization Effects 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 239000003446 ligand Substances 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 108020004999 messenger RNA Proteins 0.000 description 3
• 230000003228 microsomal effect Effects 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 235000019198 oils Nutrition 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
• 239000012188 paraffin wax Substances 0.000 description 3
• 238000012809 post-inoculation Methods 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000000284 resting effect Effects 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 235000010356 sorbitol Nutrition 0.000 description 3
• 210000000952 spleen Anatomy 0.000 description 3
• 238000010186 staining Methods 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 231100001274 therapeutic index Toxicity 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 238000000844 transformation Methods 0.000 description 3
• 229960001722 verapamil Drugs 0.000 description 3
• GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
• OSNSWKAZFASRNG-WNFIKIDCSA-N (2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;hydrate Chemical compound O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O OSNSWKAZFASRNG-WNFIKIDCSA-N 0.000 description 2
• MMMAAUAZNGRAGW-UHFFFAOYSA-N 1,4-diazepine-1-carboxamide Chemical compound NC(=O)N1C=CC=NC=C1 MMMAAUAZNGRAGW-UHFFFAOYSA-N 0.000 description 2
• ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
• PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
• UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
• 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 206010001889 Alveolitis Diseases 0.000 description 2
• 206010002091 Anaesthesia Diseases 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 102000008186 Collagen Human genes 0.000 description 2
• 108010035532 Collagen Proteins 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• 206010013975 Dyspnoeas Diseases 0.000 description 2
• 206010014561 Emphysema Diseases 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 229940126162 GABAA receptor modulator Drugs 0.000 description 2
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
• 108050003558 Interleukin-17 Proteins 0.000 description 2
• 102000013691 Interleukin-17 Human genes 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• 102000004388 Interleukin-4 Human genes 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• 229930182816 L-glutamine Natural products 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• 108010052285 Membrane Proteins Proteins 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 239000012980 RPMI-1640 medium Substances 0.000 description 2
• 229910006124 SOCl2 Inorganic materials 0.000 description 2
• 206010070834 Sensitisation Diseases 0.000 description 2
• 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 description 2
• 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 235000021355 Stearic acid Nutrition 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 125000003545 alkoxy group Chemical group 0.000 description 2
• 239000013566 allergen Substances 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 230000000172 allergic effect Effects 0.000 description 2
• 229940037003 alum Drugs 0.000 description 2
• 230000037005 anaesthesia Effects 0.000 description 2
• 230000001078 anti-cholinergic effect Effects 0.000 description 2
• 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 239000007900 aqueous suspension Substances 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• 150000001540 azides Chemical class 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 230000036983 biotransformation Effects 0.000 description 2
• 230000008499 blood brain barrier function Effects 0.000 description 2
• 210000001218 blood-brain barrier Anatomy 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 201000009267 bronchiectasis Diseases 0.000 description 2
• 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 2
• 239000007853 buffer solution Substances 0.000 description 2
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
• HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical class COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 239000000812 cholinergic antagonist Substances 0.000 description 2
• 230000001713 cholinergic effect Effects 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 229940125758 compound 15 Drugs 0.000 description 2
• 229940126142 compound 16 Drugs 0.000 description 2
• 229940125898 compound 5 Drugs 0.000 description 2
• 125000004093 cyano group Chemical group *C#N 0.000 description 2
• 230000016396 cytokine production Effects 0.000 description 2
• 238000002784 cytotoxicity assay Methods 0.000 description 2
• 231100000263 cytotoxicity test Toxicity 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 239000012055 enteric layer Substances 0.000 description 2
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
• 238000001704 evaporation Methods 0.000 description 2
• 230000008020 evaporation Effects 0.000 description 2
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 230000005021 gait Effects 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 238000003304 gavage Methods 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 125000005843 halogen group Chemical group 0.000 description 2
• 238000003306 harvesting Methods 0.000 description 2
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 230000002102 hyperpolarization Effects 0.000 description 2
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 210000004153 islets of langerhan Anatomy 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• 208000018937 joint inflammation Diseases 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 210000003292 kidney cell Anatomy 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 2
• 229960000582 mepyramine Drugs 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 210000001589 microsome Anatomy 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 238000002552 multiple reaction monitoring Methods 0.000 description 2
• ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical compound NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 description 2
• 230000003387 muscular Effects 0.000 description 2
• 238000002663 nebulization Methods 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
• 150000002825 nitriles Chemical class 0.000 description 2
• RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 2
• 230000009871 nonspecific binding Effects 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
• 238000001543 one-way ANOVA Methods 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 229960001412 pentobarbital Drugs 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 238000010149 post-hoc-test Methods 0.000 description 2
• 235000015320 potassium carbonate Nutrition 0.000 description 2
• 229910000027 potassium carbonate Inorganic materials 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 230000009325 pulmonary function Effects 0.000 description 2
• 239000011535 reaction buffer Substances 0.000 description 2
• 230000008707 rearrangement Effects 0.000 description 2
• 230000001172 regenerating effect Effects 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 230000004648 relaxation of smooth muscle Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000029058 respiratory gaseous exchange Effects 0.000 description 2
• 238000007363 ring formation reaction Methods 0.000 description 2
• 230000008313 sensitization Effects 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 239000000779 smoke Substances 0.000 description 2
• 230000016160 smooth muscle contraction Effects 0.000 description 2
• 210000004988 splenocyte Anatomy 0.000 description 2
• 239000008117 stearic acid Substances 0.000 description 2
• 230000000707 stereoselective effect Effects 0.000 description 2
• 238000003756 stirring Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 229960004793 sucrose Drugs 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 2
• 229950010357 tetrodotoxin Drugs 0.000 description 2
• CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 2
• 210000000115 thoracic cavity Anatomy 0.000 description 2
• CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 210000003437 trachea Anatomy 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
• 235000019798 tripotassium phosphate Nutrition 0.000 description 2
• 102000003390 tumor necrosis factor Human genes 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 239000002699 waste material Substances 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
• ZXOFAHRGRROAQR-UHFFFAOYSA-N 1-(isocyanomethylsulfonyl)-2-methylbenzene Chemical compound CC1=CC=CC=C1S(=O)(=O)C[N+]#[C-] ZXOFAHRGRROAQR-UHFFFAOYSA-N 0.000 description 1
• WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
• BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
• VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
• VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
• MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
• KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
• 125000006041 3-hexenyl group Chemical group 0.000 description 1
• USWINTIHFQKJTR-UHFFFAOYSA-N 3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C2C=C(S(O)(=O)=O)C(O)=CC2=C1 USWINTIHFQKJTR-UHFFFAOYSA-N 0.000 description 1
• 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• HEXVJUUOPSZTRZ-UHFFFAOYSA-N 3H-imidazo[1,5-a][1,4]diazepine-3-carboxylic acid Chemical compound C1=NC(N2C1=CN=CC=C2)C(=O)O HEXVJUUOPSZTRZ-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
• TYJOQICPGZGYDT-UHFFFAOYSA-N 4-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 TYJOQICPGZGYDT-UHFFFAOYSA-N 0.000 description 1
• KNCUEWYWBUIFTQ-UHFFFAOYSA-N 5-(8-ethynyl-6-pyridin-2-yl-4H-imidazo[1,5-a][1,4]benzodiazepin-3-yl)-1,3-oxazole Chemical compound C(#C)C=1C=CC2=C(C(=NCC=3N2C=NC=3C2=CN=CO2)C2=NC=CC=C2)C=1 KNCUEWYWBUIFTQ-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
• 239000012103 Alexa Fluor 488 Substances 0.000 description 1
• 206010003497 Asphyxia Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
• 238000010152 Bonferroni least significant difference Methods 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
• 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
• 238000011740 C57BL/6 mouse Methods 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 244000025254 Cannabis sativa Species 0.000 description 1
• 208000009132 Catalepsy Diseases 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 108010062745 Chloride Channels Proteins 0.000 description 1
• 102000011045 Chloride Channels Human genes 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 102000029816 Collagenase Human genes 0.000 description 1
• 108060005980 Collagenase Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 102100041023 Coronin-2A Human genes 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
• 102000018832 Cytochromes Human genes 0.000 description 1
• 108010052832 Cytochromes Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 208000000059 Dyspnea Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 108090000371 Esterases Proteins 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 206010064571 Gene mutation Diseases 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• 102000016354 Glucuronosyltransferase Human genes 0.000 description 1
• 108010092364 Glucuronosyltransferase Proteins 0.000 description 1
• 108010070675 Glutathione transferase Proteins 0.000 description 1
• 102000005720 Glutathione transferase Human genes 0.000 description 1
• 102000000543 Histamine Receptors Human genes 0.000 description 1
• 108010002059 Histamine Receptors Proteins 0.000 description 1
• 101100384805 Homo sapiens ARCN1 gene Proteins 0.000 description 1
• 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
• 101000748858 Homo sapiens Coronin-2A Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102000003814 Interleukin-10 Human genes 0.000 description 1
• 108090000174 Interleukin-10 Proteins 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 108090000862 Ion Channels Proteins 0.000 description 1
• 102000004310 Ion Channels Human genes 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 108090001060 Lipase Proteins 0.000 description 1
• 102000004882 Lipase Human genes 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• 210000004322 M2 macrophage Anatomy 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
• 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 101100382966 Mus musculus Ccr3 gene Proteins 0.000 description 1
• 101100394237 Mus musculus Hand1 gene Proteins 0.000 description 1
• 206010049816 Muscle tightness Diseases 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 101100323029 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) alc-1 gene Proteins 0.000 description 1
• 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• HXIWFMKFZCWXKD-UHFFFAOYSA-N OC(=O)C1=CNC=CC=N1 Chemical compound OC(=O)C1=CNC=CC=N1 HXIWFMKFZCWXKD-UHFFFAOYSA-N 0.000 description 1
• GUGCLZQUEANZKP-UHFFFAOYSA-N OC(=O)C1=NNC=CC=C1 Chemical compound OC(=O)C1=NNC=CC=C1 GUGCLZQUEANZKP-UHFFFAOYSA-N 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• 238000002123 RNA extraction Methods 0.000 description 1
• PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
• 241000785917 Savia Species 0.000 description 1
• 241001486234 Sciota Species 0.000 description 1
• 206010039897 Sedation Diseases 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• 208000032140 Sleepiness Diseases 0.000 description 1
• 206010041349 Somnolence Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• 208000010513 Stupor Diseases 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 108090001033 Sulfotransferases Proteins 0.000 description 1
• 102000004896 Sulfotransferases Human genes 0.000 description 1
• 108700012920 TNF Proteins 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 206010047853 Waxy flexibility Diseases 0.000 description 1
• 241000269368 Xenopus laevis Species 0.000 description 1
• DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 235000011054 acetic acid Nutrition 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 229940081735 acetylcellulose Drugs 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 125000004423 acyloxy group Chemical group 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 239000000048 adrenergic agonist Substances 0.000 description 1
• 230000008484 agonism Effects 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 239000003905 agrochemical Substances 0.000 description 1
• 238000003915 air pollution Methods 0.000 description 1
• 238000010210 airway hyperresponsiveness measurement Methods 0.000 description 1
• 210000005039 airway nerve Anatomy 0.000 description 1
• 210000005057 airway smooth muscle cell Anatomy 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 229940125681 anticonvulsant agent Drugs 0.000 description 1
• 239000001961 anticonvulsive agent Substances 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 239000002249 anxiolytic agent Substances 0.000 description 1
• 230000000949 anxiolytic effect Effects 0.000 description 1
• 125000005129 aryl carbonyl group Chemical group 0.000 description 1
• 125000004104 aryloxy group Chemical group 0.000 description 1
• 238000003149 assay kit Methods 0.000 description 1
• 230000001977 ataxic effect Effects 0.000 description 1
• 229940090047 auto-injector Drugs 0.000 description 1
• 210000003050 axon Anatomy 0.000 description 1
• MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
• 210000002469 basement membrane Anatomy 0.000 description 1
• 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 238000013276 bronchoscopy Methods 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 238000011088 calibration curve Methods 0.000 description 1
• 229960002504 capsaicin Drugs 0.000 description 1
• 235000017663 capsaicin Nutrition 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000008004 cell lysis buffer Substances 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 238000003570 cell viability assay Methods 0.000 description 1
• 238000012200 cell viability kit Methods 0.000 description 1
• 238000012054 celltiter-glo Methods 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 229910052729 chemical element Inorganic materials 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 238000004296 chiral HPLC Methods 0.000 description 1
• 238000013375 chromatographic separation Methods 0.000 description 1
• 235000019504 cigarettes Nutrition 0.000 description 1
• WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 229960002424 collagenase Drugs 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 229940125773 compound 10 Drugs 0.000 description 1
• 238000002591 computed tomography Methods 0.000 description 1
• 239000004020 conductor Substances 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
• 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 238000013480 data collection Methods 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 238000000586 desensitisation Methods 0.000 description 1
• 238000004807 desolvation Methods 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 235000013681 dietary sucrose Nutrition 0.000 description 1
• ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 239000008157 edible vegetable oil Substances 0.000 description 1
• 238000002001 electrophysiology Methods 0.000 description 1
• 230000007831 electrophysiology Effects 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000003912 environmental pollution Methods 0.000 description 1
• 238000011067 equilibration Methods 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 230000032050 esterification Effects 0.000 description 1
• 238000005886 esterification reaction Methods 0.000 description 1
• DANIDPUWXPDMNG-UHFFFAOYSA-N ethyl 8-ethynyl-6-(2-fluorophenyl)-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate Chemical compound CCOC(=O)C=1N=CN(C2=CC=C(C=C22)C#C)C=1CN=C2C1=CC=CC=C1F DANIDPUWXPDMNG-UHFFFAOYSA-N 0.000 description 1
• HZYHQJXUEKIREU-UHFFFAOYSA-N ethyl 8-ethynyl-6-phenyl-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate Chemical compound CCOC(=O)C=1N=CN(C2=CC=C(C=C22)C#C)C=1CN=C2C1=CC=CC=C1 HZYHQJXUEKIREU-UHFFFAOYSA-N 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 230000021824 exploration behavior Effects 0.000 description 1
• 150000004665 fatty acids Chemical group 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 239000012054 flavored emulsion Substances 0.000 description 1
• 235000020375 flavoured syrup Nutrition 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 230000004907 flux Effects 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000012631 food intake Nutrition 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 239000003517 fume Substances 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 125000004438 haloalkoxy group Chemical group 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 239000007902 hard capsule Substances 0.000 description 1
• 238000011597 hartley guinea pig Methods 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 125000006517 heterocyclyl carbonyl group Chemical group 0.000 description 1
• 239000008240 homogeneous mixture Substances 0.000 description 1
• 102000054350 human CHI3L1 Human genes 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• RGZRSLKIOCHTSI-UHFFFAOYSA-N hydron;n-methylhydroxylamine;chloride Chemical compound Cl.CNO RGZRSLKIOCHTSI-UHFFFAOYSA-N 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 230000033444 hydroxylation Effects 0.000 description 1
• 238000005805 hydroxylation reaction Methods 0.000 description 1
• 208000013403 hyperactivity Diseases 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 230000002396 hypoinsulinemic effect Effects 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000008102 immune modulation Effects 0.000 description 1
• 238000002991 immunohistochemical analysis Methods 0.000 description 1
• 231100000986 in utero exposure Toxicity 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 239000003317 industrial substance Substances 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 229940125369 inhaled corticosteroids Drugs 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 230000001057 ionotropic effect Effects 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
• ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 229960004184 ketamine hydrochloride Drugs 0.000 description 1
• 150000003951 lactams Chemical class 0.000 description 1
• 150000002596 lactones Chemical class 0.000 description 1
• QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 238000005567 liquid scintillation counting Methods 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 208000018773 low birth weight Diseases 0.000 description 1
• 231100000533 low birth weight Toxicity 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 230000004199 lung function Effects 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000037323 metabolic rate Effects 0.000 description 1
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• MCLITRXWHZUNCQ-UHFFFAOYSA-N methylcyanamide Chemical compound CNC#N MCLITRXWHZUNCQ-UHFFFAOYSA-N 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000007479 molecular analysis Methods 0.000 description 1
• 235000019799 monosodium phosphate Nutrition 0.000 description 1
• 230000003562 morphometric effect Effects 0.000 description 1
• 238000013425 morphometry Methods 0.000 description 1
• 239000004570 mortar (masonry) Substances 0.000 description 1
• 239000012120 mounting media Substances 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 210000003550 mucous cell Anatomy 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 230000003843 mucus production Effects 0.000 description 1
• 239000003158 myorelaxant agent Substances 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 150000005054 naphthyridines Chemical class 0.000 description 1
• 229920001206 natural gum Polymers 0.000 description 1
• 210000000581 natural killer T-cell Anatomy 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• 239000012053 oil suspension Substances 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
• 239000013110 organic ligand Substances 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 125000004043 oxo group Chemical group O=* 0.000 description 1
• UVBXZOISXNZBLY-UHFFFAOYSA-L palladium(2+);triphenylphosphane;diacetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UVBXZOISXNZBLY-UHFFFAOYSA-L 0.000 description 1
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
• 239000003182 parenteral nutrition solution Substances 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
• KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• UUZZMWZGAZGXSF-UHFFFAOYSA-N peroxynitric acid Chemical compound OON(=O)=O UUZZMWZGAZGXSF-UHFFFAOYSA-N 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 229950000688 phenothiazine Drugs 0.000 description 1
• GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
• LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
• 239000002798 polar solvent Substances 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 238000011533 pre-incubation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 238000000751 protein extraction Methods 0.000 description 1
• CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
• 238000009613 pulmonary function test Methods 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 150000004040 pyrrolidinones Chemical class 0.000 description 1
• ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
• 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
• JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000002040 relaxant effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 238000010825 rotarod performance test Methods 0.000 description 1
• 239000012047 saturated solution Substances 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000036280 sedation Effects 0.000 description 1
• 230000004799 sedative–hypnotic effect Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 208000013220 shortness of breath Diseases 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 230000000391 smoking effect Effects 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
• 235000019345 sodium thiosulphate Nutrition 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
• 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
• 150000008053 sultones Chemical class 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 239000002700 tablet coating Substances 0.000 description 1
• 238000009492 tablet coating Methods 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• 125000000464 thioxo group Chemical group S=* 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• ZMCBYSBVJIMENC-UHFFFAOYSA-N tricaine Chemical compound CCOC(=O)C1=CC=CC(N)=C1 ZMCBYSBVJIMENC-UHFFFAOYSA-N 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 238000007492 two-way ANOVA Methods 0.000 description 1
• 208000012783 uncoordinated gait Diseases 0.000 description 1
• 238000011870 unpaired t-test Methods 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 230000003519 ventilatory effect Effects 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 229960004175 xylazine hydrochloride Drugs 0.000 description 1